Page 1,553«..1020..1,5521,5531,5541,555..1,5601,570..»

Diabetes cases on the rise – Daily Journal – Daily Journal

Posted: May 14, 2017 at 1:40 am

After being diagnosed with diabetes, every meal became a complicated math lesson.

Barbara Goldsmith had to become vigilant about everything she put in her body. The Edinburgh resident meticulously counted carbohydrates, too many of which can spike her blood sugar level and wreak havoc on her body.

She calculated how much she has eaten, and immediately following a meal, factored in housework, gardening or some other activity so that her sugars dont rise to unsafe levels.

On top of the four different medications she takes, diabetes has shifted everything in Goldsmiths life. But changing her lifestyle has been her only option.

Lauren Witt unpacks the blood sugar monitor that she keeps with her at all times. The 29-year-old was diagnosed with Type 1 diabetes five years ago, and utilized the Johnson Memorial Health Diabetes Care Center in Franklin to learn about testing her glucose levels, managing her diet and adapting her lifestyle to the disease. Ryan Trares

The blood sugar monitor and testing strips that Lauren Witt keeps with her at all times. Witt, 29, was diagnosed with Type 1 diabetes five years ago, and utilized the Johnson Memorial Health Diabetes Care Center in Franklin to learn about testing her glucose levels, managing her diet and adapting her lifestyle to the disease. Ryan Trares

Lauren Witt sets up the blood sugar monitor and testing strips that she keeps with her at all times. If her blood sugar, or glucose, reaches a certain level, she may need an emergency shot of insulin. The 29-year-old was diagnosed with Type 1 diabetes five years ago. Ryan Trares

Lauren Witt sets up the blood sugar monitor and testing strips that she keeps with her at all times. If her blood sugar, or glucose, reaches a certain level, she may need an emergency shot of insulin. The 29-year-old was diagnosed with Type 1 diabetes five years ago. Ryan Trares

Lauren Witt sets up the blood sugar monitor and testing strips that she keeps with her at all times. If her blood sugar, or glucose, reaches a certain level, she may need an emergency shot of insulin. The 29-year-old was diagnosed with Type 1 diabetes five years ago. Ryan Trares

The different types of insulin that Lauren Witt keeps with her at all times in case of a diabetic emergency. The 29-year-old was diagnosed with Type 1 diabetes five years ago, and utilized the Johnson Memorial Health Diabetes Care Center in Franklin to learn about testing her glucose levels, managing her diet and adapting her lifestyle to the disease. Ryan Trares

Lauren Witt, 29, was diagnosed with Type 1 diabetes five years ago, and utilized the Johnson Memorial Health Diabetes Care Center in Franklin to learn about testing her glucose levels, managing her diet and adapting her lifestyle to the disease. Ryan Trares

Watch what you eat and how much you eat. If you have medication, take it. Watch your sugar, and try to stay active. Those are the main things, she said. I dont know what would happen to me if I dont do that.

More and more Johnson County residents such as Goldsmith are living with diabetes or are on their way to developing it in the future. The disease has become worryingly more prevalent throughout Indiana, growing by more than 50 percent from 2000 to 2009.

Battling the growing epidemic has required a multi-faceted approach. Health officials have focused on educating patients about ways to avoid the disease, stressing diet and exercise, and teaching how the sugars we consume impact the body.

The hope is to stem the increase of new cases, while helping people already diagnosed live healthier and minimize the impact.

Diabetes is a global epidemic. Its out of control, said Dr. Gaston Dana of Johnson Memorial Internal Medicine Specialists. Once you develop it, you have it for life. By realizing that you can make changes in lifestyle that can significantly impact that, you can possibly stop that.

Diabetes is broad term for diseases characterized by high levels of glucose, or sugar, in the blood. The disease is caused by defects in insulin production, how insulin acts in the body, or a combination of both. Insulin is a hormone necessary for the regulation of blood glucose levels.

When insulin production and action in the body works improperly, complications such as heart disease, stroke, amputation and blindness can occur. At its worst, the disease can cause death.

The disease can come in varying forms. Type 1 diabetes occurs when the immune system attacks beta cells in the pancreas, the only cells in the body that make insulin to regulate glucose.

Type 2 is the more common form, accounting for between 90 and 95 percent of all diagnosed cases of diabetes. The bodys cells start resisting insulin and not using it properly, which eventually causes the pancreas to lose the ability to make it.

Diabetes levels in Indiana, particularly Type 2, have risen sharply since 2000, climbing from 6 percent of the population to 12.9 percent. In Johnson County, 11 percent of people have the disease. Treating diabetes costs Indiana $6.6 billion in medical costs each year, according to the American Diabetes Association.

I would say its over 50 percent of our patient population that is dealing with diabetes, Dana said.

Many of those people are referred to the Diabetes Care Center at Johnson Memorial Health, where specialists help patients adapt to what is a consuming and jarring diagnosis.

No one wants to have this diagnosis. Probably 50 percent of the people who sit in front of me are angry and in denial, said Carla Duncan, a registered nurse at the Diabetes Care Center. Theyre not hearing a word that I say, so you have to find a way to connect to them.

The staff works to ensure their patients understands what their disease is and what theyll be going through. They explain the genetic factors of the disease, how things such as being overweight, skipping meals or smoking can turn the hereditary aspects of diabetes on. Medication and how it can impact the disease is also covered.

The key is to help people understand how the disease is managed now, Duncan said.

A lot of the people who come here have preconceived ideas and old beliefs about diabetes. My grandma did this, it worked for her 50 years ago, why are you telling me something different now,' she said. So just making people realize that what we knew 50 years ago is different than what we know now about diabetes.

Lauren Witt was 24 when she was diagnosed with diabetes. She noticed that she was losing a lot of weight, despite still eating the same amount she always had. Her vision would get blurry, and on one occurrence, she passed out.

A blood test confirmed that her glucose levels were incredibly high. Once doctors determined that she had Type 1 diabetes, she was referred to Duncan to help manage the disease. She helped Witt learn to take insulin, count carbohydrates and learn more about nutrition.

(Duncan) has been so helpful. I call her my diabetes mom. She always takes care of me, and I can count on her to help with whatever questions I have, she said.

In the five years since diagnosis, Witt has adapted every part of her life around the disease.

It affects everything I do. When I wake up, I need to make sure sugar is decent, that I didnt get too low during the night. When I exercise, I have to have something to eat with me because my blood sugar can drop quickly. And everything I eat I have to count, she said. A lot of people dont know a lot about food, so to learn actual nutrition helped me comprehend everything better.

Lifestyle is a huge focus for patients with diabetes, Duncan said. Many of the people they see dont exercise, eat poorly or smoke, contributing to and exasperating the situation. Misconceptions about the disease also have to be overcome.

People have to adjust the food they consume, when and how much they eat, factor in exercise and adapt to the medications.

Changing your lifestyle is probably the hardest thing in the world. We want everybody else in the world to change, but not us. When were told to change, it gets very uncomfortable, Duncan said. The key to being successful at this is helping the patient get to that point in their life, when they say theyre ready to change.

Goldsmith was diagnosed with Type 2 diabetes around 2005 but refused to change much about her life. She had always eaten whatever she wanted and didnt do much exercising.

Though she was told to watch her concentrated sugars, she didnt pay attention. She kept gaining weight, reaching 171 pounds at the most.

I knew I was diabetic, but I just didnt do anything about it. I didnt watch myself. Thats what got me out of control, she said.

But during a checkup with her doctor, a blood test revealed that Goldsmiths glucose levels were almost twice the normal levels.

(My doctor) was very upset with me. She put me on medication, and sent me to Carla, she said. Without their help I wouldnt be where I am today.

Duncan schooled Goldsmith on portion control, how to count her carbohydrates so that too much wouldnt spike her glucose levels.

Living a more active lifestyle was also very important. Goldsmith hurt her back, which prevents her from walking long distances or running. But after she eats, she makes sure to do housework, finish the dishes, take care of laundry anything to keep moving.

The more I move around after I eat, the better my blood sugar numbers will be. If you eat a meal and sit down, let it absorb, it will screw up your numbers, she said.

Following Duncans advice, Goldsmith lost 40 pounds and dropped to 133. Her blood sugar levels have stabilized and she feels better than she has for years.

In addition to her diet and exercise, she takes one pill after breakfast, and three others after dinner to help her body regulate her blood sugar. Three times a day, she has to test her blood to monitor her sugar levels.

Medical professionals measure blood sugar to determine if a patient has diabetes. A normal blood glucose level is below 5.7 percent, while diabetes is diagnosed if that level is 6.5 percent of above.

Patients need to know how different factors affect their blood sugar, how to test it and what those numbers mean.

Even most people who have had diabetes for many years cant tell me what their blood sugar should be, Duncan said.

Duncan and her staff also work with people who come to the center with prediabetes their blood glucose levels are higher than normal, but not yet reaching the level to be considered diabetes. The condition can often be reversed with lifestyle changes, such as improving your diet and getting more exercise.

They have to know how to do that, though, Duncan said.

Weight loss, exercise, diet. Most people with prediabetes need to lose a little bit of weight, probably arent as active as they need to be, she said. Our goal is more about lifestyle. By changing lifestyle, we can change that diagnosis back to normal to prevent the diagnosis of diabetes until later in life.

If you go

Diabetes education series

What: A series of workshops and informational meetings presented by the Johnson Memorial Health Diabetes Care Center teaching people about diabetes, blood sugar and other aspects of nutrition and the disease.

Where: Johnson County Public Library, Franklin Branch, 401 State St.

Next session: 1 to 3 p.m. June 22, focusing on sugars and carbohydrates, reading a food label and balancing your plate.

Additional workshop: 1 to 3 p.m. Sept. 28

Cost: Free. No registration necessary.

Information: (317) 346-3846 or JohnsonMemorial.org/Diabetes

Link:
Diabetes cases on the rise - Daily Journal - Daily Journal

Posted in Diabetes | Comments Off on Diabetes cases on the rise – Daily Journal – Daily Journal

Diabetes diagnoses rising in Kentucky, bigger problem than data shows – News- Graphic (subscription)

Posted: May 14, 2017 at 1:40 am

Recent studies are showing more frequent occurrences of diabetes in the U.S. and Kentucky, but the numbers could be even higher than they appear.

Cases of diabetes diagnoses have gone from about 6.5 percent in 2000 to 13.4 percent in 2015 in the state, according to the Kentucky Behavioral Risk Factor Surveillance survey. And about one in three people or 37 percent of Kentuckians have prediabetes, according to the Centers for Disease Control.

Scott Countians are faring better than people in eastern Kentucky, which has a higher rate of diabetes, most likely because theres less access to medical treatment in rural areas, said Cindy Caywood, a dietician and director of the Bariatric & Metabolic Center at Georgetown Community Hospital.

Prevalence of diabetes in children has also risen across the U.S., with an estimated 3,000 children in Kentucky having it.

Thats not including people who are walking around that are diabetic, but they dont know, Caywood said. The data has shown that its increased, but the prevalence of folks who have diabetes is much higher than theyre even able to capture in the data.

Most people, if they have blood sugar issues and they dont know it, theyre running high.

Symptoms of high blood sugar include constant thirst, blurry vision, frequently having to use the bathroom and fatigue, according to the Kentucky Diabetes Prevention and Control Program from 2014.

I have some people who will say, My vision was acting up, and they have no idea that that can be a direct relation to their blood sugars, Caywood said.

People not knowing they have the disease can be dangerous, Caywood said.

Usually if someone has diabetes they have other comorbidities, she said.

Circulation and heart problems are some of the conditions that often accompany diabetes. People with diabetes are two to four times more likely to have heart disease or stroke while two out of three people with diabetes die from heart disease or stroke, according to the National Diabetes Education Program. Close to 40 percent of people who visit the hospital for cardiovascular issues are diagnosed with diabetes as a secondary condition, Caywood said.

And diabetes-related hospitalization and treatment are costing Kentuckians a lot of money. Charges for inpatient hospitalizations in Kentucky related to diabetes complications in 2015 amounted to $269,148,739, according to the 2017 Kentucky Diabetes Report.

I think theres a lot of folks who cant afford their diabetes, their testing strips, their medicine, Caywood said.

The obvious cause for diabetes is weight gain, although genetics do play a role as well, Caywood said. The number of obese adults in the U.S. have increased drastically to 68 percent today from only 10 percent in 1900, Caywood said.

Although diabetes cant necessarily be cured, there are ways to treat it effectively and keep its symptoms in check.

The good news is that it responds to lifestyle changes, Caywood said.

Eating healthier and exercising regularly can help type two diabetes sufferers lose weight and could possibly reduce their need to take insulin. The key to eating healthier is mostly eating vegetables, fruits and lean proteins as well as staying away from simple carbs sugary foods such as desserts and regular sodas.

For those who find it difficult to lose weight on their own, bariatric surgery is now considered a viable treatment option for diabetics, Caywood said. In fact, patients who have bariatric surgery often see lowered blood sugar levels before leaving the hospital.

It gives them a tool to not just lose the weight but to keep the weight off, she said. If you gain it back, the issues reappear.

Caywood also believes prevention is the best way to fight diabetes.

I think we need more education on healthy eating habits and signs of prediabetes, Caywood said.

See the rest here:
Diabetes diagnoses rising in Kentucky, bigger problem than data shows - News- Graphic (subscription)

Posted in Diabetes | Comments Off on Diabetes diagnoses rising in Kentucky, bigger problem than data shows – News- Graphic (subscription)

Earnings Clues on Puma Biotechnology, Inc. (PBYI), KBR, Inc. (KBR) Analyst’s Predictions – StockNewsJournal

Posted: May 12, 2017 at 2:42 pm


USA Commerce Daily
Earnings Clues on Puma Biotechnology, Inc. (PBYI), KBR, Inc. (KBR) Analyst's Predictions
StockNewsJournal
Investors who are keeping close eye on the stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) established that the company was able to keep return on investment at -130.59 in the trailing twelve month while Reuters data showed that industry's average ...
A Look at the valuation of Puma Biotechnology, Inc. (NasdaqGS:PBYI)Business Review
The Dirty Secret to Trading Puma Biotechnology, Inc. (PBYI), TETRA Technologies, Inc. (TTI)USA Commerce Daily
Puma Biotechnology Inc (PBYI) PT Set at $40.00 by Royal Bank of CanadaMarkets Daily
Bibeypost.com -Stocks Gallery -The De Soto Edge
all 9 news articles »

Go here to read the rest:
Earnings Clues on Puma Biotechnology, Inc. (PBYI), KBR, Inc. (KBR) Analyst's Predictions - StockNewsJournal

Posted in Biotechnology | Comments Off on Earnings Clues on Puma Biotechnology, Inc. (PBYI), KBR, Inc. (KBR) Analyst’s Predictions – StockNewsJournal

Stem cells in plants and animals behave surprisingly similarly – Phys.Org

Posted: May 12, 2017 at 2:42 pm

May 12, 2017

A new study from Lund University in Sweden shows that the behaviour of stem cells in plants and animals is surprisingly similar. The researchers were able to produce mathematical equations that reveal very small differences in the behaviour of the proteins. The results can hopefully be used in stem cell research involving humans.

"The plant and animal kingdoms were separated through evolution more than 1.6 billion years ago. It is surprising that the interactions between the handful of key genes that control the fate of each stem cell are so similar in both cases", says Carsten Peterson, professor at the Faculty of Science at Lund University.

Carsten Peterson is one of the researchers behind the recent study on differences and similarities between animal and plant stem cells. With a background in theoretical physics, he and his colleagues have tackled the stem cells from a different perspective, which proved successful.

By formulating mathematical equations, the researchers have performed a detailed study of the proteins that are central to the stem cells in mammals and plants. The proteins are linked to the genes that control the stem cells. In particular, the researchers have studied how these proteins mutually affect one another through interaction as the cells evolve.

"Although the proteins in mammalian and plant stem cells are very different when studied separately, there are major similarities in the ways in which they interact, that is, how they strengthen or weaken each other", says Carsten Peterson.

Stem cells are a hot topic in medical contexts, especially when it comes to cancer and autoimmune diseases. A stem cell is capable of evolving into several different types of cells and is thus a sort of mother cell to all of the body's specialised cell types. In animals, these specialised cells can never return to a stem cell state on their own. In plants, however, they can.

"Specialised cells of plants can return to being stem cells without external manipulation. In the plant world, there is a natural reprogramming process", says Carsten Peterson.

The mathematical equations show that very small differences are sufficient to explain why plant cells are so flexible while cells of mammals require artificial reprogramming to return to a stem cell state.

"When cells are influenced externally artificially for animals or naturally for plants the minor differences in interaction play a greater role, and the differences appear to be of greater significance", says Carsten Peterson.

He believes that a lot of work remains with regard to the efficiency of reprogramming of animal cells and therefore hopes that insights from the plant world can contribute. The current study provides clues about why it is so much easier to make a cell go back to being a stem cell in plants compared to mammals.

Reprogramming is a frequently used word in stem cell contexts today, ever since the Nobel Prize in Medicine and Physiology in 2012. One of the prize winners, Shinya Yamanaka, had demonstrated how to externally manipulate cells to return to an embryonic stem cell state by increasing the concentration of certain proteins. Turning back the clock this way has enormous potential in clinical contexts. For example, on an individual basis, skin cells can be reprogrammed into embryonic stem cells, and be made into desired cell types by manipulating certain proteins. This process is known as regenerative medicine.

The study was recently published in the scientific journal PLoS ONE.

Explore further: Study shows adipose stem cells may be the cell of choice for therapeutic applications

More information: Victor Olariu et al. Different reprogramming propensities in plants and mammals: Are small variations in the core network wirings responsible?, PLOS ONE (2017). DOI: 10.1371/journal.pone.0175251

Journal reference: PLoS ONE

Provided by: Lund University

An international team of researchers, funded by Morris Animal Foundation, has shown that adipose (fat) stem cells might be the preferred stem cell type for use in canine therapeutic applications, including orthopedic diseases ...

Freiburg plant biologist Prof. Dr. Thomas Laux and his research group have published an article in the journal Developmental Cell presenting initial findings on how shoot stem cells in plants form during embryogenesis, the ...

Scientists have discovered the gene essential for chemically reprogramming human amniotic stem cells into a more versatile state similar to embryonic stem cells, in research led by UCL and Heinrich Heine University.

A protein that stays attached on chromosomes during cell division plays a critical role in determining the type of cell that stem cells can become. The discovery, made by EPFL scientists, has significant implications for ...

Researchers from the Vavilov Institute of General Genetics, Research Institute of Physical Chemical Medicine and Moscow Institute of Physics and Technology (MIPT) have concluded that reprogramming does not create differences ...

Stem cells are typically thought to have the intrinsic ability to generate or replace specialized cells. However, a team of biologists at NYU showed that regenerating plants can naturally reconstitute their stem cells from ...

New lung "organoids"tiny 3-D structures that mimic features of a full-sized lunghave been created from human pluripotent stem cells by researchers at Columbia University Medical Center (CUMC). The team used the organoids ...

University of Dundee scientists have solved a mystery concerning one of the most fundamental processes in cell biology, in a new discovery that they hope may help to tackle cancer one day.

A recent research paper in the Journal of Heredity reveals that there are three sub-species of snow leopard. Until now, researchers had assumed this species, Panthera uncia, was monotypic.

Adult stem cells have the ability to transform into many types of cells, but tracing the path individual stem cells follow as they mature and identifying the molecules that trigger these fateful decisions are difficult in ...

Leading hospital "superbugs," known as the enterococci, arose from an ancestor that dates back 450 million yearsabout the time when animals were first crawling onto land (and well before the age of dinosaurs), according ...

In their quest to replicate themselves, viruses have gotten awfully good at tricking human cells into pumping out viral proteins. That's why scientists have been working to use viruses as forces for good: to deliver useful ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See more here:
Stem cells in plants and animals behave surprisingly similarly - Phys.Org

Posted in Cell Medicine | Comments Off on Stem cells in plants and animals behave surprisingly similarly – Phys.Org

Dr. Xinping Song New prostate Natural treatment Investigates Effects of Traditional Chinese Medicine on Cancer – PR Newswire (press release)

Posted: May 12, 2017 at 2:42 pm

XIANGTAN, China, May 12, 2017 /PRNewswire/ --On average there are over 200 billion cell divisions going on in the body every day and the human body does a remarkable job ensuring that this process goes without error, however as we age and are exposed to different environmental stresses the machinery involved in cell division can wear down. If cell division is not regulated properly we can have too much cell division, resulting in excessive cell growth, this phenomenon is the underlying mechanism of cancer and how tumors are produced. Cancer cells generated during abnormal cell division often have little to no differences in composition making treatment excessively difficult. Modern day medicine and medical procedures work by targeting all cells in the region the cancerous tumor has arisen, this kills both cancer and non-cancer cells leaving extensive side effects. Sciencedaily published research news on how Chinese medicine kills cancer cells from University of Adelaide. New research in therapeutics for cancer revolves around targeting specific cancer cells.Dr. Xinping Song from the 3D Urology and Prostate Clinic in China is in one lab looking to target these cells specifically. Research from the 3D prostate clinic has shown that ancient Chinese medicines could be a novel and new prostate cancer treatment.

Researchers from Yale University and Columbia University found that triptolide effectively triggers cancer cell apoptosis. Research out of the 3D Prostate treatment has been geared towards using ancient traditional Herbal medicine for the apoptosis of cancer cells while leaving all other cells untouched. Two ancient Chinese medicines investigated by the 3D clinic lab include elemene emulsifications from rhizoma curcumae and ginseng. Principle results from the Dr. Xinping Song show that elemene could be a tumor suppressor, whereas ginseng shows promise in the recovery of patients after cancer cells have been eliminated.

The 3d prostate clinic concludes that the use of active ingredients in traditional Chinese medicines with or without the conjunction of Western medicine is a promising method to treat cancer induced tumors. Pharmacological studies still need to be done to understand any drug interactions/side effects that ancient Chinese medicine may have when paired with western pharmaceuticals, however, the research from the 3D treatments shows that there are ways to treat cancer without killing non-cancerous cells and reducing side effects.

Contact: Alisa Wang +86-186-73216429 prostatecure3d(at)gmail.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dr-xinping-song-new-prostate-natural-treatment-investigates-effects-of-traditional-chinese-medicine-on-cancer-300456424.html

SOURCE 3D Urology and Prostate Clinic

Excerpt from:
Dr. Xinping Song New prostate Natural treatment Investigates Effects of Traditional Chinese Medicine on Cancer - PR Newswire (press release)

Posted in Cell Medicine | Comments Off on Dr. Xinping Song New prostate Natural treatment Investigates Effects of Traditional Chinese Medicine on Cancer – PR Newswire (press release)

Capricor to Cut Jobs as Cardiac Cell Therapy Falters in Heart Attack Study – Genetic Engineering & Biotechnology News

Posted: May 12, 2017 at 2:41 pm

Capricor Therapeutics said it would have to cut jobs and the scope of its operations after interim data from a Phase II study evaluating its lead allogeneic cardiosphere-derived cell therapy CAP-1002 in heart attack patients showed that the trial was unlikely to meet its primary 12-month efficacy endpoint. The firm said it would now focus its resources on its Duchenne muscular dystrophy (DMD) program for CAP-1002.

The 142-patient ALLSTAR trial was evaluating CAP-1002 in adults who have experienced a large heart attack with residual cardiac dysfunction. The prespecified interim analysis on 6 months of follow-up data indicated that the study wasnt going to demonstrate a statistically significant difference in the efficacy endpoint of percent change from baseline infarct size as a percentage of left ventricular mass, measured by cardiac magnetic resonance imaging (MRI).

"The lack of a clear difference in the change in scar size from baseline to 6 months between the active and control groups in the interim observations from ALLSTAR was unexpected, admitted Linda Marbn, Ph.D., president and CEO of Capricor. These results diverge from the consistent and extensive record of activity observed with our cell technology in the setting of cardiac fibrosis as demonstrated by both preclinical and clinical studies, and we hope to gain an understanding of the factors that led to these observations through the conduct of further analyses.

Raj Makkar, M.D., co-principal investigator of the ALLSTAR Trial, and associate director for interventional technologies in the Heart Institute at Cedars-Sinai Medical Center, added, "We believe it is important to note that the observed improvements in scar size in the placebo group are markedly inconsistent with the well-established natural history of this disease process. It is certainly possible that, for a variety of reasons, the greater number of sites involved in the conduct of ALLSTAR contributed to an increase in variability seen in the scar measurements as determined by MRI."

Carpricor said it would continue to analyze cumulative ALLSTAR data, which showed no notable differences between treatment groups in ejection fraction, but did show near statistically significant reductions in mean end-diastolic volume and trends toward reduction in mean end-systolic volume associated with CAP-1002 therapy.

The firm hasnt disclosed how many jobs will have to go, but said it would now concentrate on developing CAP-1002 for the DMD indication, including the ongoing Phase I/II HOPE trial evaluating skeletal muscle performance and cardiac biomarkers in boys and young men with DMD treated using CAP-1002. Positive 6-month data from the single-dose HOPE study were reported last month.

Capricor also plans to start a repeated-dose study with intravenous CAP-1002 therapy in DMD during the second half of 2017, primarily to evaluate skeletal (noncardiac) muscle function.

Although we are disappointed, the favorable safety profile demonstrated by CAP-1002 in ALLSTAR supports the prospect of its chronic, repeat administration in patients with DMD, Dr. Marbn added. Also, the potent anti-inflammatory properties of CAP-1002 may be well-suited to mitigate DMD progression, for which chronic inflammation is believed to play a causative role."

Earlier this week Capricor confirmed raising $3.7 million in a private placement, which the firm said it would use to progress its products and for general corporate purposes. In February, Capricor reported that it was dropping its Phase II-stage heart failure drug Cenderitide and would end its license agreement with the Mayo Clinic for the natriuretic peptide receptor agonist program so that it could concentrate on its cell- and exosome-based programs.

Read more from the original source:
Capricor to Cut Jobs as Cardiac Cell Therapy Falters in Heart Attack Study - Genetic Engineering & Biotechnology News

Posted in Cell Therapy | Comments Off on Capricor to Cut Jobs as Cardiac Cell Therapy Falters in Heart Attack Study – Genetic Engineering & Biotechnology News

Blood study insight could improve stem cell therapy success – Medical Xpress

Posted: May 12, 2017 at 2:41 pm

May 12, 2017

Researchers have pinpointed a key enzyme that is vital for the production of fresh blood cells in the body. The enzyme is essential for the survival of specialised stem cells that give rise to new blood cells, the study found. Experts say the findings could help to improve the success of stem cell therapies that are being developed to treat some blood cancers and disorders of the immune system.

Enzyme

Scientists focused on an enzyme called fumarase, which is known to play a key role in the generation of energy inside cells. Children with gene mutations that affect fumarase have blood defects, which prompted researchers to investigate its function.

The mouse study found that deletion of fumarase from blood cells causes major defects in new blood cell production. These defects could be traced back to defects in the specialised stem cells that give rise to new blood cells. Blocking the enzyme causes a molecule called fumarate to build up inside the cells, which has wide-ranging toxic effects.

Stem cells

The study sheds new light on the conditions that blood stem cells need to survive, which could help to boost the success of stem cell therapies, the researchers say. Stem cell metabolism is an emerging field of research with an immense therapeutic potential. In future, we hope to identify the biochemical pathways affected by fumarate in stem cells and, by manipulating these pathways, improve the success of stem cell transplant therapies.

Professor Kamil Kranc says, "The research was prompted when researchers noticed that children with genetic mutations in the fumarase gene have blood defects."

The research was prompted when researchers noticed that children with genetic mutations in the fumarase gene have blood defects.

Scientists from the Medical Research Council Centre for Regenerative Medicine at the University of Edinburgh led the study.

The research is published in the Journal of Experimental Medicine and was funded by The Kay Kendall Leukaemia Fund, Cancer Research UK, Bloodwise, Tenovus Scotland and Wellcome.

Explore further: How blood can be rejuvenated

Researchers find key molecule that could lead to new therapies for anemia and other iron disorders

How do T cells, the beat cops of the immune system, detect signs of disease without the benefit of eyes? Like most cells, they explore their surroundings through direct physical contact, but how T cells feel out intruders ...

Bacteria in the gut microbiome drive the formation of cerebral cavernous malformations (CCMs), clusters of dilated, thin-walled blood vessels in the brain that can cause stroke and seizures, according to new research published ...

(Phys.org)A team of researchers with members from France, Korea and Germany has found that temperatures inside human mitochondria can run as high as 50C. In their paper uploaded to the preprint server bioRxiv, the group ...

The kidney - made up of about a million tiny units that work to filter blood, constantly rids the body of undesired waste products to form urine while holding back blood cells and valuable proteins, and controls the body's ...

As with coffee or alcohol, the way each person processes medication is unique. One person's perfect dose may be another person's deadly overdose. With such variability, it can be hard to prescribe exactly the right amount ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to see the original:
Blood study insight could improve stem cell therapy success - Medical Xpress

Posted in Cell Therapy | Comments Off on Blood study insight could improve stem cell therapy success – Medical Xpress

Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy – Labiotech.eu (blog)

Posted: May 12, 2017 at 2:41 pm

Celyad has received Fast Track Designation from the FDA for C-Cure, a cell therapy aimed to treat heart failure with the patients own stem cells.

Celyad is confident that the announcement of Fast Track Designation from the FDA will help it accelerate the search for a partner to develop C-Cure, a cell therapy for ischemic heart failure. After running a Phase III trial in Europe that didnt meet its primary endpoint, the Belgian biotech identified a subpopulation of more of 60% of patients that did show a significant improvement and is now determined to try again once it finds financial support.

CelyadsC-Cure technology consists in the harvest of the patients bone marrow, which is treated with growth factors and then re-injected into the heart to grow new functional muscle in the area lost due to infarction. The therapy is complementary to Celyads main focus, immuno-oncology. The company is well-known for developing an allogeneic version of the promising CAR-T technologythat recently triggered a license agreement with Novartis.

Image viaJolygon/Shutterstock

Follow this link:
Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy - Labiotech.eu (blog)

Posted in Cell Therapy | Comments Off on Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy – Labiotech.eu (blog)

One Year Follow Up of Cytori Cell Therapy in Investigator Erectile Dysfunction Trial – GlobeNewswire (press release)

Posted: May 12, 2017 at 2:41 pm

May 10, 2017 09:00 ET | Source: Cytori Therapeutics

SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc.(NASDAQ:CYTX) announces one year follow up data of ADRCs (Cytori Cell Therapy) treatment in post prostatectomy erectile dysfunction. The related abstract and presentation will occur at the 2017 American Urological Association Annual Meeting, May 12-16 in Boston. The abstract is currently available in the Journal of Urology (online).

The investigator initiated, open label, Phase I, single arm pilot trial studied 21 men with post prostatectomy erectile dysfunction with insufficient clinical effect after maximal pharmacologic intervention. The abstract reports that following a single administration of Cytori Cell Therapy, eight of 14 (57%) of subjects with urinary continence at baseline recovered their erectile function and could implement sexual intercourse after 6 months with the effect sustained to 12 months after treatment. This was associated with a modest but statistically significant sustained improvement in the patients IIEF-5 score, a widely used measure of male sexual function. Efficacy was solely demonstrated in patients that were continent at inclusion of the trial. No serious adverse events and 8 minor events related to the liposuction were reported.

This data follows previously published six month follow-up from the same trial on a smaller subset of 17 men with erectile dysfunction following radical prostatectomy (publication available here).

In addition to this study in erectile dysfunction, Cytori Cell TherapyTM is currently being studied in the ADRESU trial in Japan for male urinary incontinence following prostatic surgery. This investigator initiated, phase III, multicenter, 45 patient trial of Cytoris ECCI-50 cellular therapeutic is based on promising pilot trial data published in the International Journal of Urology in 2014. Details of the pilot trial can be found on clinicaltrials.gov and the Japanese Ministry of Health Labour and Welfare website.

AboutCytori Therapeutics, Inc.

Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytoris proprietary technologies and products. Cytori Nanomedicine is developing encapsulated therapies for regenerative medicine and oncologic indications. For more information, visit http://www.cytori.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, without limitation, conduct of clinical trials and presentation of clinical data, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, inherent risk and uncertainty in conduct of investigator-initiated clinical trials, protection of intellectual property rights, regulatory uncertainties, risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, as well as other risks and uncertainties described under the heading "Risk Factors" in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Related Articles

San Diego, California, UNITED STATES

Home

More:
One Year Follow Up of Cytori Cell Therapy in Investigator Erectile Dysfunction Trial - GlobeNewswire (press release)

Posted in Cell Therapy | Comments Off on One Year Follow Up of Cytori Cell Therapy in Investigator Erectile Dysfunction Trial – GlobeNewswire (press release)

Global CAR T Cell Therapy Market & Clinical Trials Insight 2017-2022: Clinical Pipeline of 99 Therapies – GlobeNewswire (press release)

Posted: May 12, 2017 at 2:41 pm

May 09, 2017 04:49 ET | Source: Research and Markets

Dublin, May 09, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global CAR T Cell Therapy Market & Clinical Trials Insight 2022" report to their offering.

Global CAR T Cell Therapy Market & Clinical Trials Insight 2022 report highlights the ongoing clinical and non-clinical advancement in the field of Car T Cell Therapy.

As per report findings, the promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients. Currently, there are 99 CAR T Cell based therapies in clinical pipeline and most of them belong to Phase-I and Phase-I/II clinical trials.

In recent years, researchers have identified the chimeric antigen receptor as a potential target for molecular genetics to insert a new epitopes on the receptor region which allows a degree of control of the immune system. CAR T cell therapy satisfy the need to explore new and efficacious adoptive T cell therapy. The gene transfer technology could efficiently introduce the genes encoding CARs into the immune effector cells. The transferring of engineered T cells provides the specific antigen binding in a non-major histocompatibility complex.

The promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients.

The first commercial application of CAR T Cell based therapy for the treatment of Mantle- Non-Hodgkin's lymphoma is expected to be available from 2020. The anti-CD19 CAR T cell therapy axicabtagene ciloleucel (KTE-C19) is developed by KITE Pharma in collaboration with National Cancer Institute. Currently this therapy is in preregistration phase.

In future, the advancement of CAR T Cell therapy will be largely driven by academia and will require the support for the expensive early phase clinical trials which promise to cover the way for a new form of targeted, exportable immunotherapy for cancer patient. The manufacturing of CD19 CAR T cell therapy CTL019 is in a way which will modernize the process of using the therapy globally. The anticipation of regulatory and manufacturing issues before they arise and proactively addressing the concerns helps to accelerate the process of bringing this promising therapeutic approach to more patients in future.

Global CAR T Cell Therapy Market & Clinical Trials Insight 2022 report highlights:

- CAR T Cell Therapies Delivery Pipeline & Mechanism of Action - Global CAR T Cell Therapy Clinical Trials for Cancer Treatment - Global CAR T Cell Therapies Clinical Pipeline by Company, Indication & Phase - Global CAR T Cell Therapies Clinical Pipeline: 99 Therapies - CAR T Cell Therapies in Highest Phase: Preregistration - Majority of CAR T Cell Therapies in Phase-I/II Trials: 16 Therapies - Global Market Scenario of CAR T Cell Therapy - Global CAR T Cell Therapy Market Future Prospects

Key Topics Covered:

1. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology 1.1 Overview 1.2 History & Development of CAR-T Technology

2. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design 2.1 Structure of CAR T Cell 2.2 1nd Generation Chimeric Antigen Receptor 2.3 2nd & 3nd Generation CAR T Cell

3. Principle of Chimeric Antigen Receptor Design 3.1 CAR Modified T Cells: Targeting 3.2 CAR Modified T Cell: Signaling

4. CAR T Cell Therapies Delivery Pipeline & Mechanism of Action 4.1 Process of CAR T Cell Therapy 4.2 Mechanism of Action

5. Approaches to Improve the CAR T Cell Therapy 5.1 Introduction 5.2 Targeting the Tumor Stroma with CAR T Cells 5.3 Targeting the Cytokine Networks 5.4 Combination Strategies for CAR T Cells 5.5 Targeting the Immune Checkpoints

6. Global CAR T Cell Therapy Clinical Trials for Cancer Treatment 6.1 Acute Lymphoblastic Leukemia 6.2 Multiple Myeloma 6.3 Brain Tumors 6.4 Lymphoma 6.5 Solid Tumors

7. Global CAR T Cell Therapies Clinical Pipeline by Company, Indication & Phase 7.1 Research 7.2 Preclinical 7.3 Clinical 7.4 Phase-I 7.5 Phase-I/II 7.6 Phase-II 7.7 Preregistration

8. Global Market Scenario of CAR T Cell Therapy 8.1 Overview 8.2 Estimated Price Analysis of CAR T Cell Therapy

9. Global Market Size of CAR T Cell Therapy 9.1 Market Share of Cancer Immunotherapy by its Technology 9.2 CAR T Cell Therapy Market Value

10. Global CAR T Cell Therapy Market Dynamics 10.1 Favorable Parameters 10.2 Challenges

11. Global CAR T Cell Therapy Market Future Prospects

12. Competitive Landscape 12.1 Autolus 12.2 Bellicum 12.3 Bluebird 12.4 Celgene 12.5 Cellectis 12.6 Celyad 12.7 Eureka Therapeutics 12.8 Fortress Biotech 12.9 Immune Therapeutics 12.10 Juno Therapeutics 12.11 Kite Pharma 12.12 Novartis 12.13 Sorrento therapeutics 12.14 TILT Biotherapeutics 12.15 Ziopharm

For more information about this report visit http://www.researchandmarkets.com/research/6tj28w/global_car_t_cell

Related Articles

Research and Markets Logo

LOGO URL | Copy the link below

Formats available:

Visit link:
Global CAR T Cell Therapy Market & Clinical Trials Insight 2017-2022: Clinical Pipeline of 99 Therapies - GlobeNewswire (press release)

Posted in Cell Therapy | Comments Off on Global CAR T Cell Therapy Market & Clinical Trials Insight 2017-2022: Clinical Pipeline of 99 Therapies – GlobeNewswire (press release)

Page 1,553«..1020..1,5521,5531,5541,555..1,5601,570..»